Current evidences on the XPG Asp1104His polymorphism and melanoma susceptibility: a meta-analysis based on case-control studies

被引：7

作者：

Xu, Yuanzhi ^{[1
]}

Jiao, Guangjun ^{[2
]}

Wei, Li ^{[3
,4
]}

Wang, Ning ^{[3
]}

Xue, Yajun ^{[1
]}

Lan, Jin ^{[1
]}

Wang, Yajie ^{[3
]}

Liu, Chuan ^{[3
]}

Lou, Meiqing ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Neurosurg, Shanghai 200080, Peoples R China

[2] Peking Univ, Musculoskeletal Tumor Ctr, Peoples Hosp, Beijing 100871, Peoples R China

[3] Second Mil Med Univ, Changhai Hosp, Dept Oncol, Shanghai 200433, Peoples R China

[4] PLA, Hosp 401, Dept Oncol, Qingdao, Shandong, Peoples R China

来源：

MOLECULAR GENETICS AND GENOMICS | 2015年 / 290卷 / 01期

关键词：

XPG Asp1104His; Polymorphism; Melanoma; Meta-analysis; NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; CUTANEOUS MELANOMA; GENE POLYMORPHISMS; CANCER; RISK; ASSOCIATION; EPIDEMIOLOGY; EXPRESSION; PREVENTION;

D O I：

10.1007/s00438-014-0917-2

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Previous studies evaluating the association between the XPG Asp1104His polymorphism and melanoma susceptibility remained controversial. To draw a more precise estimation of the relationship, a total of eight published case-control studies containing 5,212 cases and 7,045 controls were included for meta-analysis. Overall, a significant association was found between the XPG Asp1104His polymorphism and melanoma susceptibility for the dominant model (OR = 2.42, 95 % CI = 2.26-2.60). In subgroup analysis by source of control, there was an obvious association was found among Population-based subgroup for the dominant model CC+GC vs GG (OR 2.51, 95 % CI 2.28-2.77), among the Hospital-based subgroup, an obvious association was also found for the dominant model CC+GC vs GG (OR 2.34, 95 % CI 2.12-2.58). This meta-analysis suggested that the XPG Asp1104His polymorphism was a risk factor for melanoma susceptibility.

引用

页码：273 / 279

页数：7

共 44 条

[1] The interpretation of random-effects meta-analysis in decision models [J].

Ades, AE ;

Lu, G ;

Higgins, JPT .

MEDICAL DECISION MAKING, 2005, 25 (06) :646-654

[2]

[Anonymous], PHARMACOGENOMICS

[3] Strong functional interactions of TFIIH with XPC and XPG in human DNA nucleotide excision repair, without a preassembled repairosome [J].

Araújo, SJ ;

Nigg, EA ;

Wood, RD .

MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (07) :2281-2291

[4] XPG mRNA Expression Levels Modulate Prognosis in Resected Non-Small-Cell Lung Cancer in Conjunction with BRCA1 and ERCC1 Expression [J].

Bartolucci, Roberta ;

Wei, Jia ;

Sanchez, Jose Javier ;

Perez-Roca, Laia ;

Chaib, Imane ;

Puma, Francesco ;

Farabi, Raffaele ;

Mendez, Pedro ;

Roila, Fausto ;

Okamoto, Tatsuro ;

Taron, Miquel ;

Rosell, Rafael .

CLINICAL LUNG CANCER, 2009, 10 (01) :47-52

[5] OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].

BEGG, CB ;

MAZUMDAR, M .

BIOMETRICS, 1994, 50 (04) :1088-1101

[6] No association between three xeroderma pigmentosum group C and one group G gene polymorphisms and risk of cutaneous melanoma [J].

Blankenburg, S ;

König, IR ;

Moessner, R ;

Laspe, P ;

Thoms, KM ;

Krueger, U ;

Khan, SG ;

Westphal, G ;

Volkenandt, M ;

Neumann, C ;

Ziegler, A ;

Kraemer, KH ;

Reich, K ;

Emmert, S .

EUROPEAN JOURNAL OF HUMAN GENETICS, 2005, 13 (02) :253-255

[7] The XPG story [J].

Clarkson, SG .

BIOCHIMIE, 2003, 85 (11) :1113-1121

[8] THE COMBINATION OF ESTIMATES FROM DIFFERENT EXPERIMENTS [J].

COCHRAN, WG .

BIOMETRICS, 1954, 10 (01) :101-129

[9]

Dean E, 2012, EXPERT REV ANTICANC, V12, P1437, DOI [10.1586/era.12.124, 10.1586/ERA.12.124]

[10] METAANALYSIS IN CLINICAL-TRIALS [J].

DERSIMONIAN, R ;

LAIRD, N .

CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188

← 1 2 3 4 5 →